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Regulatory T (Treg) cells are essential for maintaining
immune homeostasis. Although Foxp3 expression
marks the commitment of progenitors to Treg cell
lineage, how Treg cells are generated during
lymphocyte development remains enigmatic. We
report here that the c-Rel transcription factor
controlled development of Treg cells by promoting
the formation of a Foxp3-specific enhanceosome.
This enhanceosome contained c-Rel, p65, NFAT,
Smad, and CREB. Although Smad and CREB first
bound to Foxp3 enhancers, they later moved to the
promoter to form the c-Rel enhanceosome. c-Rel-
deficient mice had up to 90% reductions of Treg cells
compared to wild-type mice, and c-Rel-deficient
T cells were compromised in Treg cell differentiation.
Thus, Treg cell development is controlled by a c-Rel
enhanceosome, and strategies targeting Rel-NF-kB
can be effective for manipulating Treg cell function.INTRODUCTION
Regulatory T (Treg) cells are a heterogeneous population of T
lymphocytes that play crucial roles in maintaining immune
homeostasis and preventing autoimmune diseases (Bommir-
eddy and Doetschman, 2007; Lohr et al., 2006; Sakaguchi
et al., 2006; Shevach et al., 2006). The CD4+CD25+Foxp3+
(forkhead box P3+) ‘‘naturally occurring’’ Treg (nTreg) cells are
generated in the thymus and are among the best-studied Treg
cells (Sakaguchi et al., 2006). In mice, nTreg cells appear to
migrate to the periphery by day 3 after birth, because thymec-
tomy at day 3, but not after, leads to autoimmunity. Thymic
development of Treg cells requires T cell receptor (TCR) and
costimulatory signaling as shown by the fact that mice deficient
in these molecules have reduced nTreg cell numbers (Sakagu-
chi et al., 2006). Thymic stromal cells not only provide the
peptide-MHC complexes to engage immature TCRs, but they
are also the source of secondary signals involved in dictating
lineage commitment. Reports indicate that the development of
Foxp3+ thymocytes is linked to that of the medullary thymic
epithelium. The majority of Foxp3-expressing thymocytes are
localized to the medullary region of the thymus (Fontenot
et al., 2005a).932 Immunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc.Unlike nTreg cells, the CD4+CD25+Foxp3+ ‘‘induced’’ Treg
(iTreg) cells can be generated in peripheral lymphoid organs, or
in cultures, after stimulation with antigens and Treg cell-inducing
cytokines such as transforming growth factor (TGF)-b (Chen
et al., 2003; Bommireddy and Doetschman, 2007; Liang et al.,
2005; Lohr et al., 2006). In addition to nTreg and iTreg cells, other
types of Treg cells have also been described. These include
CD8+ Treg cells, Tr1 cells, and Th3 cells (Chen et al., 1994;
O’Garra and Vieira, 2004; Shevach, 2006).
The Foxp3 protein is the most distinct marker of nTreg cells
and is crucial for their function. Scurfy mice that carry a Foxp3
gene mutation present lymphoproliferation, lymphocytic infiltra-
tion, and multiorgan autoimmune diseases (Godfrey et al., 1991).
Similarly, Foxp3 gene mutation in humans causes a fatal
autoimmune disorder called IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked) (Bennett et al.,
2001). Foxp3 protein, named for its winged helix-forkhead DNA
binding domain, functions as a transcription factor. Full-length
Foxp3 holds high sequence homology across mammalian
species (Fontenot et al., 2005b). Scurfy affects males, but not
heterozygous females, because Foxp3 gene is located on X
chromosome. Random X inactivation in heterozygous females
results in a combination of cells with normal and defective
Foxp3 expression (Tommasini et al., 2002). Scurfy mice are
deficient in CD4+CD25+ T cells, and autoimmune diseases in
these mice can be prevented by adoptive transfer of
CD4+CD25+Foxp3+ Treg cells (Bennett et al., 2001; Khattri
et al., 2003).
Although Foxp3 gene expression marks the commitment of
progenitor cells to Treg cell lineage, transcription factors that
switch on the Foxp3 gene during T cell development are not
well defined. The Foxp3 gene is controlled by a core promoter
and at least three distal enhancers (Lal et al., 2009; Mantel
et al., 2006; Tone et al., 2008). Whether a single enhanceosome
(i.e., enhancer complex) that bridges all these regulatory
elements or multiple modular enhancer complexes are formed
in Treg cells is not known. Recent studies indicate that transcrip-
tion factors NFAT (nuclear factor of activated T cells) and Smad
may play crucial roles in activating the Foxp3 gene (Tone et al.,
2008). However, mice deficient in one or two of these factors
have no substantial reductions in Treg cell numbers
(Bommireddy and Doetschman, 2007; Bopp et al., 2005), indi-
cating that other factors are required for Treg cell differentiation.
The mammalian Rel or nuclear factor (NF)-kB family consists
of five members: c-Rel, RelA-p65, RelB, NF-kB1 (p50-p105),
and NF-kB2 (p52-p100) (Barnes and Karin, 1997; Beg and
Figure 1. Intrathymic Development of CD4+CD25+Foxp3+ Regula-
tory T Cells Is Markedly Abated in Rel/ Mice
Thymocytes from wild-type (WT) and Rel/ C57BL/6 mice (n = 6) were
collected 3, 7, 21, and 42 days after birth, stained with antibodies to CD4,
CD8, CD25, and Foxp3, and analyzed by flow cytometry.
(A) Contour plots of gated CD4+ T cells. The number in each panel represents
the percentage of CD4+ T cells in the gated area.
(B) Total cell numbers and the percentages of different thymocyte subsets.
Error bars represent the SD of the means. The differences between WT and
Rel/ groups are statistically significant (p < 0.001) for the following cell
subsets: CD4+CD8CD25+, CD4+CD8Foxp3+, and CD4+CD8CD25+Foxp3+
cells. Results are representative of three independent experiments.
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c-Rel and Regulatory T CellsBaltimore, 1996). Unlike other members that are constitutively
expressed in multiple cell types, c-Rel is expressed primarily in
lymphoid tissues by lymphoid and myeloid cells (Brownell
et al., 1987; Gerondakis et al., 1998; Huguet et al., 1998; Simek
and Rice, 1988; Wang et al., 1997). c-Rel-deficient mice do not
suffer from developmental problems or infectious diseases,
and c-Rel-deficient T cells are competent in survival and T helper
2 (Th2) cell-type responses, but are markedly compromised in
their Th1 cell-type responses (Hilliard et al., 2002; Tumang
et al., 1998). We report here that c-Rel plays a crucial role in
assembling a Foxp3-specific enhancer complex that is required
for initiating Treg cell differentiation.
RESULTS
Treg Cell Development Is Markedly Diminished
in c-Rel-Deficient Mice
The thymus is the central lymphoid organ that gives rise to both
Foxp3+ Treg cells and Foxp3 naive T cells (Fontenot and
Rudensky, 2005; Kim, 2006; Kim and Rudensky, 2006; Sakagu-
chi, 2005; Ziegler, 2006). c-Rel is a member of the Rel-NF-kB
family that is preferentially expressed in lymphoid organs (Simek
and Rice, 1988). To determine the roles of c-Rel in the develop-
ment of Treg and naive T cells, we examined their frequencies
in the thymus of 3-, 7-, 21-, and 42-day-old C57BL/6 mice that
do or do not express c-Rel (Figure 1). Although the total number
of thymocytes was reduced by 20% in c-Rel-deficient
(Rel/) mice, the frequencies of CD4+CD25Foxp3 naive
T cells were comparable in the two groups. By contrast, up to
90% reductions of CD4+CD25+Foxp3+ nTreg cells were
observed in c-Rel-deficient thymus of both neonatal and
adult mice (Figure 1). For 6-week-old mice, the frequency of
CD4+CD8CD25+Foxp3+ nTreg cells was reduced from
2.7% ± 0.9% in the wild-type (WT) group to 0.2% ± 0.1% in
the c-Rel-deficient group (p < 0.001) (Figure 1). Consistent with
this finding, the frequencies of CD4+CD25+Foxp3+ Treg cells
were also markedly reduced in the spleens of c-Rel-deficient
mice, regardless of ages (Figure S1 and Table S1 available
online). Up to 75% reductions were observed on day 3 and
80% reductions were observed on day 42 in the c-Rel-deficient
group (Table S1). These results indicate that c-Rel is required for
the thymic development of CD4+CD25+Foxp3+ nTreg cells but is
dispensable for that of Foxp3 naive T cells.
c-Rel-Deficient T Cells Are Defective in Foxp3 Gene
Expression and iTreg Cell Differentiation
To determine the effect of c-Rel deficiency on Foxp3 gene
expression and Treg cell differentiation, we measured Foxp3
mRNA expression in T cells by quantitative PCR. We found
that Foxp3 mRNA was markedly reduced in splenic CD4+
T cells isolated from c-Rel-deficient mice after stimulation with
either anti-CD3 plus anti-CD28 or phorbol myristate acetate
(PMA) plus ionomycin (Figure 2A). Similarly, when purified naive
T cells were cultured under Treg cell-inducing conditions in vitro,
Foxp3 mRNA expression was significantly reduced in the c-Rel-
deficient group (Figure 2B). Consistent with these findings, the
frequency of iTreg cells generated in the culture was also
significantly reduced in the c-Rel-deficient group (Figures 2C
and 2D). To ensure that Treg cells, but not Th17 cells, wereIgenerated in our cultures, cells were also tested for IL-17 expres-
sion (Figure 2C). Additionally, when overexpressed, c-Rel
increased Foxp3 expression in both primary T cells and the
EL-4 T cell line (Figure S2). Thus, c-Rel may directly control iTreg
cell differentiation through Foxp3 gene.c-Rel and p65 Activate the Foxp3 Promoter
To test the hypothesis that Rel-NF-kB proteins control Foxp3
gene expression, we first determined whether they activate the
Foxp3 promoter in a luciferase-based promoter reporter assay.
We found that c-Rel and p65, but not p50 or RelB, significantlymmunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc. 933
Figure 2. c-Rel Deficiency Blocks Foxp3 Gene Expression and Treg
Cell Differentiation
(A) Splenic CD4+ T cells were purified from 6-week-old WT and Rel/ mice
(n = 5) and stimulated with anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) for
6 hr or with PMA (50 ng/ml) and ionomycin (1 mM) for 2 hr. Total RNA was
extracted and Foxp3 mRNA expression was determined by real-time RT-PCR.
Graph shows mean ± SD of triplicate cultures.
(B) Purified CD4+CD25 splenic T cells were cultured in the presence of plate-
bound anti-CD3 (5 mg/ml), soluble anti-CD28 (1 mg/ml), IL-2 (50 U/ml), anti-IL-4
(1 mg/ml), anti-IFN-g (1 mg/ml), and TGF-b (5 ng/ml) for the indicated times.
Total RNA was extracted and Foxp3 mRNA expression was determined by
real-time RT-PCR. Graph shows mean ± SD of triplicate cultures.
(C and D) CD4+CD25 T cells were cultured as in (B) for 3 days, restimulated
with PMA (50 ng/ml) and ionomycin (1 mM) for 4 hr, stained with antibodies
to IL-17A and Foxp3, and analyzed by flow cytometry. Numbers indicate the
percentages of cells expressing Foxp3 and/or IL-17A. (D) shows mean ± SD
of triplicate cultures.
(E–H) EL4-LAF cells were transiently transfected with murine Foxp3 promoter
luciferase constructs together with an expression vector for full-length (E)
c-Rel, (F) p65, (G) p50, or (H) RelB, or the empty vector as indicated. After
24 hr, cells were treated with or without PMA and ionomycin for 5 hr, and
the luciferase activities were measured. The promoter activity (mean ± SD) is
presented as fold increase over cells transfected with empty vector but not
treated with PMA and ionomycin. To normalize the transfection efficiency
across samples, the Renilla luciferase expression vector pRLTK was used
as an internal control. *The differences between the two groups are statistically
significant (p < 0.001). Data are representative of three independent
experiments.
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934 Immunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc.activated the Foxp3 promoter upon coexpression (Figures
2E–2H). Of note is the fact that the Foxp3 promoter activity
was extremely weak in the absence of coexpressed c-Rel or
p65, a finding consistent with previous reports about this
promoter (Mantel et al., 2006; Tone et al., 2008). These results
indicate that p50 and RelB may not be as crucial as c-Rel for
Treg cell differentiation. Consistent with this view, p50-deficient
mice have only slightly reduced numbers of Treg cells in the
spleen, but not in the thymus when compared to WT mice
(Figure S3), and RelB-deficient mice have relatively normal
numbers of Treg cells (Figure S4). Taken together, these findings
indicate that members of the Rel-NF-kB family may regulate
Foxp3 gene expression during Treg cell development in a
member-specific manner.c-Rel Binds to the Foxp3 Promoter through Two Unique
Rel-NFAT Sites
To identify the c-Rel-responsive region in the murine Foxp3
promoter, we performed deletional analysis of the promoter.
We found that nucleotides 498 to 144 were required for the
c-Rel activity (Figure 3A). A close examination of the murine
nucleotide sequence in this region revealed two putative
Rel-NF-kB binding sites (382 to 376 and 327 to 321)
that are identical in sequence to previously designated NFAT
sites in the human FOXP3 promoter (Mantel et al., 2006). NFAT
and c-Rel can bind to same nucleotides (containing TTCC) on
many gene promoters because they both use the N-terminal
Rel homology domain (conserved between them) to bind DNA
(Rao et al., 1997). To determine whether these sites are required
for c-Rel action, we mutated nucleotides TTCC (position379 to
376) to TGGA. This mutation substantially reduced the effect of
c-Rel on the promoter (Figure 3B), indicating that c-Rel regulates
Foxp3 promoter through this site.
To establish whether c-Rel is indeed able to bind to the NFAT
nucleotides, we performed nucleotide pull-down analyses with
both wild-type and mutant NFAT nucleotides. We found that
similar to NFATc2, c-Rel readily bound to the 33-mer nucleotides
of both NFAT sites, but not their mutants (Figure 3C). For these
reasons, we named these sites the ‘‘Rel-NFAT’’ sites.c-Rel Orchestrates the Formation of a Foxp3-Specific
Enhanceosome
To determine the nature of the transcriptional complexes formed
at the Foxp3 locus during Treg cell differentiation, we performed
chromatin immunoprecipitation (ChIP) and sequential ChIP
(SeqChIP or Re-ChIP). The Foxp3 DNA:transcription factor
complexes were precipitated with specific antibodies to c-Rel,
p65, NFATc2, Smad3, and pCREB (phospho-cAMP response
element binding protein) at different time points of Treg cell
differentiation. The nature of the precipitated DNA was then
defined by PCR with primers specific for the core promoter or
each of the two enhancers of the Foxp3 gene as detailed in
Experimental Procedures. Re-ChIP was used to ascertain
whether c-Rel and NFAT simultaneously associated with the
same DNA sequence. In the Re-ChIP, c-Rel:DNA complexes
from the first immunoprecipitation (with anti-c-Rel) were
subjected to an additional round of immunoprecipitation with
anti-NFATc2 (Figure 4).
Figure 3. c-Rel Activates the Foxp3 Promoter through Unique Rel/
NFAT Sites
(A) Deletion mutants of the Foxp3 promoter were analyzed in a luciferase
reporter assay as in Figure 2 with or without c-Rel cotransfection. Binding sites
for Rel-NFATc2 and Sp1 are indicated. The promoter activity (mean ± SD) is
presented as fold increase over cells transfected with empty vector but not
treated with PMA and ionomycin.
(B) Wild-type and Rel-NFAT site-mutated Foxp3 promoters were analyzed in
a luciferase reporter assay as in Figure 2 with or without c-Rel cotransfection.
The promoter activity (mean ± SD) is presented as fold increase over cells
transfected with empty vector but not treated with PMA and ionomycin.
(C) Binding of c-Rel to Rel-NFAT oligonucleotides as determined by nucleotide
pull-down. Nuclear extracts were prepared from EL4-LAF cells after stimula-
tion for 6 hr with PMA and ionomycin. Biotinylated Rel-NFAT oligonucleotides
or their mutants were absorbed by streptavidin-agarose beads and then
added to the nuclear extracts. The amount of c-Rel and NFATc2 proteins in
the precipitates were assessed by immunoblotting with anti-c-Rel and anti-
NFATc2, respectively. Total nuclear extract were also tested as controls.
Data are representative of three independent experiments.
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c-Rel and Regulatory T CellsWe found that in resting CD4+CD25 T cells, the Foxp3
promoter and enhancers were completely devoid of any
transcription factors tested (time 0, Figure 4A). By 0.5 hr after
stimulation with Treg cell-inducing factors, c-Rel, p65, and
NFATc2 started to appear at the promoter site whereas Smad
bound to enhancer 1 and pCREB occupied both enhancers 1
and 2. Remarkably, 8 hr after stimulation, both Smad and pCREB
completely dissociated from the enhancers, but emerged at the
promoter site, coinciding with a strong occupation of the
promoter by c-Rel, p65, and NFATc2 (Figure 4A). By the 19th
hour, c-Rel and pCREB disappeared from the promoter with
NFATc2, Smad, and p65 remaining. Of the five transcription
factors tested, c-Rel and p65 appeared to be the first to occupy
the promoter; their binding peaked at the 2nd hour as opposed to
8th hour for other factors. Re-ChIP assay confirmed that c-Rel
and NFATc2 were indeed in the same complex (Figure 4A).
TGF-b is important in iTreg cell generation. To determine its
effect on the assembly of the c-Rel enhanceosome, we repeated
the ChIP and re-ChIP assays by using cells that were not treated
with exogenous TGF-b (Figure 4B). We found that TGF-b affectedIprimarily the recruitment of Smad to the Foxp3 promoter while
having little effect on that of other transcription factors tested.
The expression of Foxp3 mRNA was extremely low in cultures
without exogenous TGF-b and did not increase during Treg cell
differentiation as measured by real-time PCR (Figure 5). However,
a small, but detectable number of Treg cells were generated in the
absence of exogenous TGF-b, as determined by flow cytometry
(Figure 5). In the presence of TGF-b, Foxp3+ T cells increased
from 0.82% to 17% during the first 18 hr of Treg cell differenti-
ation and reached 40% at the end of the culture. Thus,
TGF-b-dependent recruitment of SMAD to the Foxp3 enhanceo-
some is likely required for the generation of iTreg cells.
c-Rel Regulates Treg Cell Differentiation
in a Cell-Autonomous Manner
IL-2 is important in Treg cell development (Lohr et al., 2006).
c-Rel-deficient T cells have a partial defect in IL-2 production
when cultured in vitro (Liou et al., 1999). To determine the degree
to which c-Rel regulates iTreg cell differentiation independent of
IL-2, we studied iTreg cell differentiation in the presence of
a neutralizing IL-2 antibody. Although anti-IL-2 significantly
reduced the number of iTreg cells generated, c-Rel-deficient
T cells were equally defective in iTreg cell differentiation,
indicating that they have an intrinsic defect in the Treg cell differ-
entiation program (Figures 6A and 6B). To ensure that Treg cells,
but not Th17 cells, were generated in our cultures, cells were also
tested for IL-17 expression (Figure 6A). Combined with the
finding that c-Rel-deficient T cells were defective in iTreg cell
differentiation even when treated with excess amounts of IL-2
(Figures 2B–2D), these results indicate that IL-2 may not be
responsible for the defective Treg cell differentiation of c-Rel-
deficient T cells in the culture. Therefore, c-Rel may directly
control Treg cell differentiation in a cell-autonomous manner.
To test this hypothesis, we generated two types of mixed bone
marrow chimeric mice in which the WT and Rel/ bone marrow
cells were present at different ratios. We found that Rel/ bone
marrow cells gave rise to markedly fewer Foxp3+CD4+ Treg cells
than did WT bone marrow cells regardless of the bone marrow
cell ratios used (Figures 6C and 6D). This was true in both the
thymus and the spleen of the recipient mice. Thus, Rel/
T cells have an intrinsic defect in their Treg cell differentiation
program.
DISCUSSION
How Treg cells are generated remains enigmatic. Results
reported here enable us to propose a c-Rel-dependent enhan-
ceosome model, which may apply to both iTreg and nTreg cells.
Thus, antigen-presenting cells (APC) carrying specific peptides
engage precursor T cells by TCR and CD28, in the presence of
TGF-b (Chen et al., 2003; Kretschmer et al., 2006; Tang et al.,
2003); ligation of TCR, CD28, and TGF-b receptors leads to the
activation of IKKb, which phosphorylates IkBa (inhibitor of
kBa), releasing c-Rel and p65. We propose that the freed
c-Rel-p65 dimer migrates into the nucleus, binds to the Foxp3
promoter, and induces the formation of a Treg cell-specific
multifactorial transcriptional complex called ‘‘enhanceosome,’’
which comprises transcription factors that bind not only to the
promoter but also to the distal enhancers (such as CREB andmmunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc. 935
Figure 4. Formation of a Unique c-Rel Enhanceosome
at the Foxp3 Promoter
Purified CD4+CD25 T cells from C57BL/6 mice were cultured
under Treg cell-inducing conditions as in Figure 2B in the
presence (A) or absence (B) of recombinant TGF-b and
harvested at the indicated times. Cells were then analyzed
by ChIP for c-Rel, p65, NFATc2, Smad3, and pCREB bindings
to the promoter, enhancer-1, and enhancer-2 of the Foxp3
gene as described in Experimental Procedures. Re-ChIP
was performed for NFATc2 binding to the promoter with
DNA precipitated by anti-c-Rel. Control IgG and input DNA
shown are for promoter ChIP. Data are representative of three
independent experiments.
Immunity
c-Rel and Regulatory T CellsSmad). The Treg cell-specific enhanceosome in turn serves as
the ‘‘on-and-off’’ switch of the Foxp3 gene and the Treg cell
differentiation program. This model is consistent with reports
that mice deficient in IKKb (inhibitor of kB kinase b) or doubly
deficient in two Rel-NF-kB members have reduced
CD4+CD25+ T cells, although Foxp3+ Treg cells in these mice
were not determined (Schmidt-Supprian et al., 2003; Zheng
et al., 2003).
If the Foxp3 promoter is regulated by a multifactorial tran-
scriptional complex, how is c-Rel deficiency alone able to mark-
edly abate Treg cell differentiation? We propose that the c-Rel-
containing Foxp3 enhanceosome operates as a ‘‘coincidence
detector,’’ turning on Foxp3 promoter only when all the essential
transcription factors are present (either sequentially or concur-
rently), and lacking any one of them leaves the promoter
dormant (Merika and Thanos, 2001). This model also explains
how Treg cell-specific Foxp3 gene expression can be specified
by factors such as c-Rel, p65, Smad, and NFAT that are not
strictly Treg cell specific. The presence of any of these factors
alone is insufficient to drive Foxp3 gene expression, and the
presence of all these factors, which may occur only under
Treg cell-inducing condition, is required for Treg cell differentia-
tion. Many gene promoters follow the principle of the enhance-
some model (Merika and Thanos, 2001). Thus, in order to initiate
the Treg cell differentiation program, at least four classes of tran-
scription factors, i.e., NFAT, Smad, CREB, and c-Rel, must be936 Immunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc.transported to the Foxp3 promoter. Manipulating
the function of any of these factors is sufficient to
alter the Treg cell differentiation program. It is to
be noted that, unlike c-Rel-deficient mice that
have a severe defect in Treg cell differentiation,
mice deficient in one or two of the Smad or NFAT
family members have no marked reductions in
Treg cell numbers (Bommireddy and Doetschman,
2007; Bopp et al., 2005). This may be due to
compensation by other members of the Smad or
NFAT family, which may form the enhanceosome
together with c-Rel. This notion is supported by
the report that Stim1- and Stim2-deficient mice,
which have defects in the activation of all NFAT
proteins, have reduced Treg cells (Oh-Hora et al.,
2008).
How enhancers enhance the activities of
promoters that are kilobases away has puzzled
biologists for decades. It is generally acceptedthat enhancer-binding factors can form large transcriptional
complexes with promoter-binding factors to enhance the
promoter activity. This may be achieved by three distinct, but
not mutually exclusive, processes, which are known as ‘‘loop-
ing,’’ ‘‘scanning,’’ and ‘‘linking’’ mechanisms (Bondarenko
et al., 2003). Because we did not detect an association between
the enhancers and c-Rel, p65, or NFATc2, we propose that the
enhancers may not loop back to the promoter to form the enhan-
ceosome. Instead, after engaging their specific enhancers,
Smad and CREB may simply scan the Foxp3 locus until they
reach the promoter complex formed by c-Rel, p65, and NFAT,
leading to the maturation of the enhanceosome. Similar
scanning mechanism has been previously proposed for other
genes (Bondarenko et al., 2003). However, although the
scanning mechanism explains all the ChIP data we report here,
we do not know all the components of the c-Rel enhanceosome
formed at the Foxp3 promoter. Nor can we rule out the possibility
that Smad and NFAT found at the promoter and enhancers are
from different pools of factors. Scaffold proteins are crucial for
enhanceosome formation (Merika and Thanos, 2001). Their
role in the formation of the c-Rel enhanceosome remains to be
established.
The Foxp3 gene is ‘‘turned off’’ in most cell types by at least
two epigenetic mechanisms: (1) its close association with
histones (which prevents its access by activating factors), and
(2) its methylation in the regulatory regions (which makes it
Figure 5. Foxp3 Expression during Treg Cell
Differentiation with or without TGF-b
Purified CD4+CD25 splenic T cells were cultured in the presence
of plate-bound anti-CD3, soluble anti-CD28, IL-2, anti-IL-4, and
anti-IFN-g, with or without exogenous TGF-b (4 ng/ml) for the
indicated times.
(A) Cells were stained with antibodies to CD4 and Foxp3 and
analyzed by flow cytometry. Graphs show contour plots of gated
CD4+ T cells. The number in each graph represents the
percentage of CD4+ T cells in the gated area.
(B) Total RNA was extracted and Foxp3 mRNA levels were
determined by real-time RT-PCR. Graph shows means ± SD
of triplicate cultures. The differences between WT and Rel/
groups are statistically significant (p < 0.001) for all data points
after 6 hr. Results are representative of two independent
experiments.
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c-Rel and Regulatory T Cells‘‘unreadable’’ by activating factors) (Baron et al., 2007; Janson
et al., 2008; Kim and Leonard, 2007; Lal et al., 2009; Mantel
et al., 2006; Polansky et al., 2008; Tone et al., 2008). In order
to ‘‘switch on’’ the Foxp3 gene and to maintain stable Foxp3
expression, the histones that cover Foxp3 DNA have to be
acetylated and removed, and the methylated DNA regions of
the Foxp3 gene have to be demethylated. These epigenetic
changes at the Foxp3 locus are hallmarks of nTreg cells and
are the reason why the Foxp3 gene is on in Treg cells but off in
non-Treg cells.Immunity 31The epigenetic changes at the Foxp3 locus are likely
initiated by the enhanceosome identified in this study.
Both Rel-NF-kB and pCREB can directly recruit
histone-modifying enzymes, e.g., histone acetyltrans-
ferases p300 and CBP (CREB-binding protein). Addi-
tionally, the c-Rel enhanceosome may also control
DNA methylation by blocking the access of DNA meth-yltransferase to cytosine residues. Further studies are needed to
test these possibilities.
In addition to reducing Foxp3 expression, c-Rel deficiency
also affected CD25 expression. This may be a result of reduced
generation of Treg cells. Alternatively, it may be caused by
a reduced CD25 promoter and enhancer activity in Rel/ cells.
Regardless of the mechanism of reduced CD25 expression, our
demonstration that c-Rel regulates iTreg development indepen-
dent of IL-2 (the ligand for CD25) indicates that the c-Rel-Foxp3
axis is crucial for the generation of Treg cells.Figure 6. c-Rel Regulates Treg Cell Development in
a Cell-Autonomous Manner
(A) Purified CD4+CD25 T cells from 6-week-old WT and Rel/
mice (n = 5) were cultured in the presence of plate-bound anti-
CD3, soluble anti-CD28, anti-IL-2 (1 mg/ml), anti-IL-4, anti-IFN-g,
and TGF-b for 3 days, restimulated with PMA and ionomycin for
4 hr, stained with antibodies to IL-17A and Foxp3, and analyzed
by flow cytometry.
(B) Percentages of CD4+Foxp3+ cells after in vitro Treg cell differ-
entiation as shown in (A), in the presence or absence of anti-IL-2.
*p < 0.001.
(C) Mixed bone marrow chimeric mice were generated by injecting
T cell-depleted bone marrow cells from CD45.2+ Rel/ or WT
C57BL/6 mice, mixed with CD45.1+ WT bone marrow cells at
a ratio of 1:4 (CD45.2+:CD45.1+), into irradiated CD45.2+ WT
C57BL/6 recipients (n = 4). Seven weeks later, the frequencies
of Foxp3+CD4+CD45.2+ cells were determined by flow cytometry.
*p < 0.01.
(D) Mixed bone marrow chimeric mice were generated by injecting
T cell-depleted CD45.2+ Rel/ bone marrow cells, mixed with
CD45.1+ WT bone marrow cells at a ratio of 1:1 (CD45.2+:
CD45.1+), into irradiated CD45.2+ C57BL/6 recipients (n = 3).
Seven weeks later, the frequencies of Foxp3+CD4+ cells were
determined by flow cytometry. Connected symbols indicate
values from the same mouse. Results are representative of three
independent experiments.
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c-Rel and Regulatory T CellsBecause many immunosuppressive drugs currently used for
treating inflammatory diseases inhibit the Rel-NF-kB pathway,
they may also inadvertently block Treg cell differentiation.
However, because c-Rel is also required for humoral immunity
and Th1 (but not Th2) cell-mediated immunity (Hilliard et al.,
2002; Tumang et al., 1998), c-Rel inhibition or deficiency alone
may not lead to enhanced autoimmunity. Thus, results reported
here not only help advance our understanding of the Treg cell
differentiation program, but may also aid in developing new
drugs for combating inflammatory diseases.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (B6) mice that carry a Rel gene null mutation were generated as
described and were backcrossed to B6 mice for 12 generations before being
used in this study (Hilliard et al., 2002; Liou et al., 1999). B6, CD45.1+ B6,
B6;129, RelB-deficient B6, NF-kB1-deficient B6;129, and RAG-1-deficient
B6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All
mice were housed in the University of Pennsylvania animal care facilities under
pathogen-free conditions and all procedures were preapproved by the
institutional animal care and use committee.
Generation of Bone Marrow Chimeras
Bone marrow cells were isolated from WT and Rel/ C57BL/6 mice that
express either CD45.1 or CD45.2 and were depleted of T cells with biotin-
anti-TCRb (H57-597; BD PharMingen) and streptavidin-labeled magnetic
beads (Miltenyi Biotec). For one of the bone marrow chimeras, WT bone
marrow cells from CD45.1+ C57BL/6 mice were mixed with either WT or
Rel/ CD45.2+ bone marrow cells at a ratio of 4:1 (CD45.1+:CD45.2+). For
another chimera, bone marrow cells from WT CD45.1+ C57BL/6 mice were
mixed with Rel/ CD45.2+ bone marrow cells at a ratio of 1:1 (CD45.1+:
CD45.2+). Bone marrow cells, 10–15 million per recipient, were transferred
by intravenous injection into sublethally irradiated (500 rads, two times spaced
3 hr apart) C57BL/6 mice. Seven weeks later, mice were sacrificed, and the
Foxp3 expression in T cells was analyzed by flow cytometry.
Antibodies and Flow Cytometry
Fluorescein isothiocyanate-conjugated anti-Foxp3 and phycoerythrin (PE)-
conjugated anti-IL-17A were purchased from BD PharMingen. PE-conjugated
anti-CD4, cyanine-5-conjugated anti-CD8, and allophycocyanin-conjugated
anti-CD25 were purchased from Caltag Laboratories. Flow cytometric
analyses were performed on freshly isolated thymocytes and splenocytes
and cultured T cells. For intracellular staining, cells were fixed in Fixation/Per-
meabilization solution (BD Biosciences) and treated with specific antibodies
per manufacturer’s protocols. Stained cells were analyzed on a FACS-Calibur
(BD Biosciences). Data were analyzed with the FlowJo software.
Chromatin Immunoprecipitation Assay
ChIP was performed with the ChIP assay kit, per the manufacturer’s instruc-
tions (Upstate Biotechnology). In brief, cells were fixed with 1% formaldehyde
at room temperature for 10 min and lysed in the lysis buffer. DNA was
then fragmented by sonication. After preclearance for 1 hr at 4C with
salmon sperm DNA-saturated protein A-agarose, chromatin solutions were
immunoprecipitated overnight at 4C with 1 mg of rabbit antibodies to c-Rel,
p65, NFATc2, pCREB (Santa Cruz Biotechology, Inc.), Smad3 (Abcam), or
control rabbit IgG. Input and immunoprecipitated chromatins were incubated
for 4 hr at 65C to reverse cross-links. After proteinase K digestion, DNA
was extracted with phenol/chloroform and precipitated with ethanol.
ChIP DNA was then analyzed by PCR with the following primer sets: Foxp3-
promoter-forward: 50-CTTCCCATTCACATGGCAGGC-30; Foxp3-promoter-
reverse: 50-TTGCCCTTTACGAGTCATCTG-30; enhancer-1-forward: 50-CCCA
TGTTGGCTTCCAGTCTCCTTTATGG-30; enhancer-1-reverse: 50-AGGTACA
GAGAGGTTAAGAGCCTGGGT-30; enhancer-2-forward: 50-TGTGACAACAG
GGCCCAGAT-30;enhancer-2-reverse: 50-GCGTTCCTGTTTGACTGTTTCTT-30.
The PCR products, which correspond to nucleotides 501 to 239 of the938 Immunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc.promoter, +2093 to +2248 of enhancer-1, and +4495 to +4595 of enhancer-2
were analyzed by electrophoresis on 2% agarose gels.Real-Time RT-PCR
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Reverse transcription was performed with
oligo dT primers. Real-time PCR was carried out in an Applied Biosystems
7500 system with Power SYBR Green PCR Master Mix (Applied Biosystems).
Relative levels of gene expression were determined with GAPDH as the
control. The following primers were used to amplify mouse Foxp3 gene:
forward, 50-CAGCTGCCTACAGTGCCCCTAG-30; reverse, 50-CATTTGCCAG
CAGTGGGTAG-30.Nucleotide Pull-Down Assay
EL4/LAF cells (Tone et al., 2008) were stimulated with 50 ng/ml PMA (Sigma)
and 1 mM ionomycin (Sigma) for 6 hr at 37C. The cells were resuspended in
lysis buffer (20 mM HEPES, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
1 mM DTT, and 0.1% Nonidet P-40) with protease inhibitors, and incubated
on ice for 15 min. Insoluble materials were removed by centrifugation.
100 mg lysate protein was diluted with dilution buffer (which is same as lysis
buffer, but without NaCl) and incubated with 10 mg of poly(deoxyinosinic-deox-
ycytidylic acid) (Roche) and 50 ml of streptavidin-agarose beads (Sigma)
carrying biotinylated oligonucleotides (as described below) for 3 hr at 4C.
The beads were washed twice with dilution buffer, resuspended in 50 ml 23
SDS sample loading buffer (BioRad), and heated to 95C for 10 min. The
eluants were resolved by SDS-PAGE. c-Rel and NFATc2 molecules were
detected by immunoblotting with specific antibodies (Santa Cruz Biotech-
nology). The oligonucleotides containing either the wild-type or mutated Rel/
NFAT binding sites used in this study are: Foxp3-NFATc2-382, 50-TTGTG
ATTTGACTTATTTTCCCTCAGTTTTTTT-30; Foxp3-NFATc2-382 mutant, 50-TT
GTGATTTGACTTATTTGGACTCAGTTTTTTT-30; Foxp3-NFATc2-327, 50- TTT
AAGAAATTGTGGTTTCTCATGAGCCCTGTT-30; Foxp3-NFATc2-327 mutant,
50-TTTAAGAAATTCTGGCGCATCATGAGCCCTGTT-30.Promoter Luciferase Assay
The pGL4-based constructs containing the 1.88 kb fragment of the murine
Foxp3 promoter or promoter deletion mutants were described previously
(Tone et al., 2008). Site-directed mutagenesis of Rel/NFAT binding site was
performed with the QuickChange kit (Stratagene), according to manufac-
turer’s instructions. DNA sequencing was used to confirm the mutated
nucleotides. EL4/LAF cells (Tone et al., 2008) were transfected with reporter
constructs together with c-Rel-, p65-, p50-, or RelB-expression vector or
empty vector with Lipofectamine LTX reagent (Invitrogen). After 24 hr, cells
were treated with or without 50 ng/ml PMA and 1 mM ionomycin for 4–5 hr
and the luciferase activities of whole-cell lysates were analyzed with the
dual-luciferase reporter assay system (Promega). Cotransfection with the
Renilla-luciferase expression vector pRL-TK (Promega) was performed in all
reporter assays. For all samples, the assays were repeated at least three times
and the data were normalized for transfection efficiency by dividing firefly
luciferase activity by that of the Renilla luciferase.Regulatory T Cell Differentiation
Splenic CD4+CD8–CD25– T cells were purified by magnetic cell sorting (MACS)
(Miltenyi Biotec) and cultured at 1.53 106/well in 24-well plates precoated with
anti-CD3 (5 mg/ml) in the presence of 1 mg/ml anti-CD28, 1 mg/ml anti-IL-4,
1 mg/ml anti-IFN-g, and 5 ng/ml TGF-b1, with or without 50 U/ml recombinant
mouse IL-2 or 1 mg /ml purified anti-mouse IL-2. Three days later, cells were
washed and treated for 4–5 hr with 50 ng/ml PMA and 1 mM ionomycin in
the presence of GolgiStop (1:1500 dilution, BD PharMingen) at 37C before
being examined by flow cytometry.Statistical Analyses
c2 analysis was used to evaluate the statistical significance of the differences
in the percentages of cells, and Student’s t test was used to evaluate the
statistical significance of mRNA, protein, and promoter activities.
Immunity
c-Rel and Regulatory T CellsSUPPLEMENTAL DATA
Supplemental Data include four figures and one table and can be found with
this article online at http://www.cell.com/immunity/supplemental/S1074-
7613(09)00503-2.
ACKNOWLEDGMENTS
The authors thank R. Carmody, W. Chen, and S. Gong for valuable discussions
and J. DeVirgiliis for technical support. Supported by grants from the National
Institutes of Health (AI50059, DK070691, and AI069289).
Received: March 25, 2009
Revised: September 23, 2009
Accepted: October 9, 2009
Published online: December 17, 2009
REFERENCES
Barnes, P.J., and Karin, M. (1997). Nuclear factor-kappaB: a pivotal transcrip-
tion factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071.
Baron, U., Floess, S., Wieczorek, G., Baumann, K., Gru¨tzkau, A., Dong, J.,
Thiel, A., Boeld, T.J., Hoffmann, P., Edinger, M., et al. (2007). DNA
demethylation in the human FOXP3 locus discriminates regulatory T cells
from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 37, 2378–2389.
Beg, A.A., and Baltimore, D. (1996). An essential role for NF-kappaB in
preventing TNF-alpha-induced cell death. Science 274, 782–784.
Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J.,
Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., and Ochs, H.D.
(2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21.
Bommireddy, R., and Doetschman, T. (2007). TGFbeta1 and Treg cells:
alliance for tolerance. Trends Mol. Med. 13, 492–501.
Bondarenko, V.A., Liu, Y.V., Jiang, Y.I., and Studitsky, V.M. (2003).
Communication over a large distance: enhancers and insulators. Biochem.
Cell Biol. 81, 241–251.
Bopp, T., Palmetshofer, A., Serfling, E., Heib, V., Schmitt, S., Richter, C., Klein,
M., Schild, H., Schmitt, E., and Stassen, M. (2005). NFATc2 and NFATc3
transcription factors play a crucial role in suppression of CD4+ T lymphocytes
by CD4+ CD25+ regulatory T cells. J. Exp. Med. 201, 181–187.
Brownell, E., Mathieson, B., Young, H.A., Keller, J., Ihle, J.N., and Rice, N.R.
(1987). Detection of c-rel-related transcripts in mouse hematopoietic tissues,
fractionated lymphocyte populations, and cell lines. Mol. Cell. Biol. 7,
1304–1309.
Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., and Weiner, H.L. (1994).
Regulatory T cell clones induced by oral tolerance: Suppression of
autoimmune encephalomyelitis. Science 265, 1237–1240.
Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., and
Wahl, S.M. (2003). Conversion of peripheral CD4+CD25- naive T cells to
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor
Foxp3. J. Exp. Med. 198, 1875–1886.
Fontenot, J.D., and Rudensky, A.Y. (2005). A well adapted regulatory
contrivance: regulatory T cell development and the forkhead family
transcription factor Foxp3. Nat. Immunol. 6, 331–337.
Fontenot, J.D., Dooley, J.L., Farr, A.G., and Rudensky, A.Y. (2005a).
Developmental regulation of Foxp3 expression during ontogeny. J. Exp.
Med. 202, 901–906.
Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and
Rudensky, A.Y. (2005b). Regulatory T cell lineage specification by the forkhead
transcription factor foxp3. Immunity 22, 329–341.
Gerondakis, S., Grumont, R., Rourke, I., and Grossmann, M. (1998). The
regulation and roles of Rel/NF-kappa B transcription factors during
lymphocyte activation. Curr. Opin. Immunol. 10, 353–359.
Godfrey, V.L., Wilkinson, J.E., Rinchik, E.M., and Russell, L.B. (1991). Fatal
lymphoreticular disease in the scurfy (sf) mouse requires T cells that matureIin a sf thymic environment: Potential model for thymic education. Proc. Natl.
Acad. Sci. USA 88, 5528–5532.
Hilliard,B.A., Mason, N.,Xu, L.,Sun,J., Lamhamedi-Cherradi, S.-E., Liou, H.-C.,
Hunter, C., and Chen, Y.H. (2002). Critical roles of c-Rel in autoimmune
inflammation and helper T cell differentiation. J. Clin. Invest. 110, 843–850.
Huguet, C., Bouali, F., Enrietto, P.J., Stehelin, D., Vandenbunder, B., and
Abbadie, C. (1998). The avian transcription factor c-Rel is expressed in
lymphocyte precursor cells and antigen-presenting cells during thymus
development. Dev. Immunol. 5, 247–261.
Janson, P.C., Winerdal, M.E., Marits, P., Tho¨rn, M., Ohlsson, R., and Winqvist,
O. (2008). FOXP3 promoter demethylation reveals the committed Treg
population in humans. PLoS ONE 3, e1612.
Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. (2003). An essential role
for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337–342.
Kim, C.H. (2006). Migration and function of FoxP3+ regulatory T cells in the
hematolymphoid system. Exp. Hematol. 34, 1033–1040.
Kim, H.P., and Leonard, W.J. (2007). CREB/ATF-dependent T cell receptor-
induced FoxP3 gene expression: a role for DNA methylation. J. Exp. Med.
204, 1543–1551.
Kim, J.M., and Rudensky, A. (2006). The role of the transcription factor Foxp3
in the development of regulatory T cells. Immunol. Rev. 212, 86–98.
Kretschmer, K., Apostolou, I., Jaeckel, E., Khazaie, K., and von Boehmer, H.
(2006). Making regulatory T cells with defined antigen specificity: Role in
autoimmunity and cancer. Immunol. Rev. 212, 163–169.
Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E.P., Reid,
S.P., Levy, D.E., and Bromberg, J.S. (2009). Epigenetic regulation of Foxp3
expression in regulatory T cells by DNA methylation. J. Immunol. 182,
259–273.
Liang, S., Alard, P., Zhao, Y., Parnell, S., Clark, S.L., and Kosiewicz, M.M.
(2005). Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells
in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201,
127–137.
Liou, H.C., Jin, Z., Tumang, J., Andjelic, S., Smith, K.A., and Liou, M.L. (1999).
c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector
function. Int. Immunol. 11, 361–371.
Lohr, J., Knoechel, B., and Abbas, A.K. (2006). Regulatory T cells in the
periphery. Immunol. Rev. 212, 149–162.
Mantel, P.Y., Ouaked, N., Ru¨ckert, B., Karagiannidis, C., Welz, R., Blaser, K.,
and Schmidt-Weber, C.B. (2006). Molecular mechanisms underlying FOXP3
induction in human T cells. J. Immunol. 176, 3593–3602.
Merika, M., and Thanos, D. (2001). Enhanceosomes. Curr. Opin. Genet. Dev.
11, 205–208.
O’Garra, A., and Vieira, P. (2004). Regulatory T cells and mechanisms of
immune system control. Nat. Med. 10, 801–805.
Oh-Hora, M., Yamashita, M., Hogan, P.G., Sharma, S., Lamperti, E., Chung,
W., Prakriya, M., Feske, S., and Rao, A. (2008). Dual functions for the
endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation
and tolerance. Nat. Immunol. 9, 432–443.
Polansky, J.K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A., Baron, U.,
Olek, S., Hamann, A., von Boehmer, H., and Huehn, J. (2008). DNA methylation
controls Foxp3 gene expression. Eur. J. Immunol. 38, 1654–1663.
Rao, A., Luo, C., and Hogan, P.G. (1997). Transcription factors of the NFAT
family: Regulation and function. Annu. Rev. Immunol. 15, 707–747.
Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+
regulatory T cells in immunological tolerance to self and non-self. Nat.
Immunol. 6, 345–352.
Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z.,
Shimizu, J., Takahashi, T., and Nomura, T. (2006). Foxp3+ CD25+ CD4+
natural regulatory T cells in dominant self-tolerance and autoimmune disease.
Immunol. Rev. 212, 8–27.
Schmidt-Supprian, M., Courtois, G., Tian, J., Coyle, A.J., Israe¨l, A., Rajewsky,
K., and Pasparakis, M. (2003). Mature T cells depend on signaling through the
IKK complex. Immunity 19, 377–389.mmunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc. 939
Immunity
c-Rel and Regulatory T CellsShevach, E.M. (2006). From vanilla to 28 flavors: Multiple varieties of T
regulatory cells. Immunity 25, 195–201.
Shevach, E.M., DiPaolo, R.A., Andersson, J., Zhao, D.M., Stephens, G.L., and
Thornton, A.M. (2006). The lifestyle of naturally occurring CD4+ CD25+ Foxp3+
regulatory T cells. Immunol. Rev. 212, 60–73.
Simek, S., and Rice, N.R. (1988). Detection and characterization of the protein
encoded by the chicken c-rel protooncogene. Oncogene Res. 2, 103–119.
Tang, Q., Henriksen, K.J., Boden, E.K., Tooley, A.J., Ye, J., Subudhi, S.K.,
Zheng, X.X., Strom, T.B., and Bluestone, J.A. (2003). Cutting edge: CD28
controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J.
Immunol. 171, 3348–3352.
Tommasini, A., Ferrari, S., Moratto, D., Badolato, R., Boniotto, M., Pirulli, D.,
Notarangelo, L.D., and Andolina, M. (2002). X-chromosome inactivation
analysis in a female carrier of FOXP3 mutation. Clin. Exp. Immunol. 130,
127–130.940 Immunity 31, 932–940, December 18, 2009 ª2009 Elsevier Inc.Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M.L., Greene, M.I., and Tone, M.
(2008). Smad3 and NFAT cooperate to induce Foxp3 expression through its
enhancer. Nat. Immunol. 9, 194–202.
Tumang, J.R., Owyang, A., Andjelic, S., Jin, Z., Hardy, R.R., Liou, M.L., and
Liou, H.C. (1998). c-Rel is essential for B lymphocyte survival and cell cycle
progression. Eur. J. Immunol. 28, 4299–4312.
Wang, W., Tam, W.F., Hughes, C.C., Rath, S., and Sen, R. (1997). c-Rel is
a target of pentoxifylline-mediated inhibition of T lymphocyte activation.
Immunity 6, 165–174.
Zheng, Y., Vig, M., Lyons, J., Van Parijs, L., and Beg, A.A. (2003). Combined
deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement
for nuclear factor kappaB in regulating mature T cell survival and in vivo
function. J. Exp. Med. 197, 861–874.
Ziegler, S.F. (2006). FOXP3: Of mice and men. Annu. Rev. Immunol. 24,
209–226.
